SWITZERLAND – Roche is set to participate in the International Society on Thrombosis and Haemostasis (ISTH) 2021 congress with new data on standard care for Haemophilia A. This virtual event will have Roche provide data that will include final analysis from the phase 3b STASEY study of Hemlibra (emicizumab) and updated data from the phase I/II study of SPK-8011, an AAV-based gene therapy in development by Spark Therapeutics (a member of the Roche Group). Roche’s STASEY study is one of the largest open-label studies primarily assessing the safety and tolerability…
Read MoreRoche set to participate at International Society on Thrombosis and Haemostasis 2021 congress
